Published in Int J Cardiol on May 28, 2015
Dabigatran approaching the realm of heparin-induced thrombocytopenia. Blood Res (2016) 0.75
Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. J Thromb Thrombolysis (2016) 0.75
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol (2013) 4.58
Perioperative atrial fibrillation and the long-term risk of ischemic stroke. JAMA (2014) 3.59
Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol (2014) 2.18
Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol (2016) 1.43
Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients: a subanalysis of the ORIGIN trial. Int J Cardiol (2014) 0.93
Polypills: essential medicines for cardiovascular disease secondary prevention? J Am Coll Cardiol (2014) 0.91
Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study. Heart Rhythm (2015) 0.86
Dabigatran etexilate and reduction in serum apolipoprotein B. Heart (2015) 0.83
Management of patients with implantable cardioverter-defibrillators and pacemakers who require radiation therapy. Heart Rhythm (2015) 0.82
World Heart Federation Emerging Leaders Program: An Innovative Capacity Building Program to Facilitate the 25 × 25 Goal. Glob Heart (2015) 0.81
Global cardiovascular research training for implementation science, health systems research, and health policy research. J Am Coll Cardiol (2015) 0.81
Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother (2015) 0.80
Reducing Premature Cardiovascular Morbidity and Mortality in People With Atherosclerotic Vascular Disease: The World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease. Glob Heart (2015) 0.77
The detection and treatment of subclinical atrial fibrillation: evaluating the IMPACT of a comprehensive strategy based on remote arrhythmia monitoring. Eur Heart J (2015) 0.76
Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart (2016) 0.76
Genome-Wide Association Study Identifies That the ABO Blood Group System Influences Interleukin-10 Levels and the Risk of Clinical Events in Patients with Acute Coronary Syndrome. PLoS One (2015) 0.76
Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol (2017) 0.76
Wealth and cardiovascular health: a cross-sectional study of wealth-related inequalities in the awareness, treatment and control of hypertension in high-, middle- and low-income countries. Int J Equity Health (2016) 0.75
Heparin bridging in peri-procedural management of new oral anticoagulant: a bridge too far? Eur Heart J (2014) 0.75
What Do Implanted Cardiac Monitors Reveal About Atrial Fibrillation? JAMA Cardiol (2017) 0.75
Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. J Am Heart Assoc (2017) 0.75
Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. Am J Med (2017) 0.75
Early Life Risk Factors for Incident Atrial Fibrillation in the Helsinki Birth Cohort Study. J Am Heart Assoc (2017) 0.75
North American Thrombosis Forum, AF Action Initiative Consensus Document. Am J Med (2016) 0.75
Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights From the ARISTOTLE Trial. Am J Med (2017) 0.75
Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. Cardiovasc Drugs Ther (2017) 0.75
The Dx-AF study: a prospective, multicenter, randomized controlled trial comparing VDD-ICD to VVI-ICD in detecting sub-clinical atrial fibrillation in defibrillator patients. J Interv Card Electrophysiol (2017) 0.75
Impact of a Genetic Risk Score on Myocardial Infarction Risk Across Different Ethnic Populations. Can J Cardiol (2016) 0.75
Diet and Major Renal Outcomes: A Prospective Cohort Study. The NIH-AARP Diet and Health Study. J Ren Nutr (2016) 0.75
Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial. Int J Cardiol (2016) 0.75
Secondary CV Prevention in South America in a Community Setting: The PURE Study. Glob Heart (2016) 0.75
Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. Heart (2015) 0.75